Liver / GI Flashcards
Acute liver failure
- no cirrhosis
- liver injury
- coagulopaty
- encephalopathy
- < 26 weeks (jaundice –> HE time)
- hyper acute < 1 week
- acute 1-4 weeks
- subacute 4-12 weeks
Causes of ALF
- paracetamol toxicity
- Drug induced - abx, AED, recreational
- viral hepatitis, A B E EBV CMV
- ischaemic
- pregnancy
Budd - chiari syndrome
hepatic vein obstruction - clot / tumour
abdo pain, hepatomegaly, gross ascites
Manifestations of ALF
Failure of
- gluconeogenesis - hypoglycaemia
- ammonia clearance - hyperammonaemia
- lactate clearance - lactic acidosis
- synthetic function - coagulopathy
Other featutes
- ARDS
- hypotension / low SVR / high CO
- Raised ICP, cerebral oedema
- AKI
Hepatic encephalopathy
ammonia not cleared by liver
crosses BBB
Ammonia + glutamate –> glutamine in brain
glutamine - apoptosis, mitochondrial dysfunction
cerebral oedema, raised ICP
Acute liver screen
Assessing disease severity
- PT / INR / coagulation screen
- LFTs, conjugated/unconjugated bilirubin, CK, LDH
- Assessment of renal function
- ABG, lactate, arterial ammonia
Assessing aetiology
- Urine toxicology screen
- serum paracetamol
- Viral screen
- HBsAg, Anti-HBC IgM
- Anti-HAV IgM
- Anti- HEV IgM
- Anti-HSV IgM
- Anti-VZV IgM
- CMV PCR
- HSV PCR
- EBV PCR
- Parvovirus PCR
- VZV PCR
- Autoimmune screen
- ANA, ASMA, anti-soluble liver antigen, ANCA, globulin profile
Lipase
Amyalse
Standard care ALF
Glucose infusion 10-20%
stress ulcer prophyalxis
restrist clotting factors unless bleeding
NAC
avoid sedatives, nephrotoxic and hepatotoxic drugs
HE –. Critical care
Intubate if Gr 3 HE
antibiotics if inflammatory, haemodynamic alteration or progressive HE
Normal Na, Mg, Pho, K
Critical care management of ALF
Specialist - aetiology, transplant, TIPSS (variceal bleed, refractory ascites
Supportive care
- Resp : HFNO > NIV. low PEEP (ICP vs ARDS)
- intubate for gr 3 HE
- fluid resuscitation, Norad first line
- nutrition
- CVVH (ammonia removal > 150)
- antimicrobials
- avoid toxins
- NAC
Prevention of encephalopaty
- thiamine, lactulose, rifaximin, RRT
Referral to specialist centre
Paracetamol / hyper acute
- pH < 7.3 / bicarb < 18
- INR > 3 day 2 or > 4 after
- oliguria / elevated creatinine
- hypoglycaemia
- altered consciousness
- lactate unresponsive to fluid
Non-paracetamol
- pH < 7.3
- INR > 1.8
- oliguria, renal failure, Na < 130
- encephalopathy, hypoglycaemia, acidosis
- Bili > 300
- Shrinking liver size
Poor prognosis in ALF-
- more severe liver injury
- extra hepatic organ failures
- subacute presentations
transplant should be considered in those fulfilling Kings College criteria
Kings College criteria
Paracetamol
- pH < 7.25 after resusictation or
- latate > 3 or
- All 3 of INR > 6.5, creat > 300, gr 3 HE
Non-paracetamol
- INR > 6.5 or
- 3 out of 5
- Indeterminate or drug induced aetiology
- age < 10 or > 40
- jaundice - HE > 7 days
- Bili > 300
- INR > 3.5
transplant contraindications
substance misuse, overwhelming sepsis, refractory shock, uncontrolled intracranial hypertension
Alcohol
- alcoholic hepatitis
- > 2 episodes in 2 year of non-adherence with medical care
- > 2 episode’s in 2 years of returning to drinking
- illicit drug use
Specific complications in ALF
Coagulpathy - vit K, use TEG, avoidance f clotting factors unless bleeding
Ascites - low sodium, diuresis, drain if SBP or resp compromise
- portopulmonary hypertension - pulmonary vasodilators (hepatopulmonary syndrome = hypoxaemia and SOB sure to pulmonary dilation and shunting)
Decompensated liver disease
acute decompensation of cirrhotic liver failure with 1 or more of:
- jaundice
- worsening ascites
- overt encephalopathy
- GI haemorrhage
- bacterial infections
- coagulopathy
Acute on chronic liver failure
- pre-existing liver failure
- decompensation
- 1 or more organ failure (CLIF-SOFA) 1a –> 3
Portal hypertension
= relatively elevated pressure in hepatic portal venous system
clinically significant if > 10mmHg
Clinical effects
- ascites (serum - ascites albumin gradient > 11g/L)
- porto-systemic shunts - varices
- decompensation
Managed by
- salt restriction
- diuresis
- NSBB - carvedilol / propanolol
- TIPSS
Hepatorenal syndrome
renal failure - infrarenal vasoconstriction, splanchnic vasodilation, pro-inflammatory, abnormal tubular electrolyte handling leading to tubular damage
HRS-AKI
- cirrhosis iwith asicate
- AKI (ICA 1-3)
- Absence of shock and nephrotoxins
- no response to 2 consecutive days of diuretic withdrawal and volume epxnaion
- no signs of structural kidney disease
Treatment
- Noradrenaline / terlipressin, albumin, treat underlying infections, RRT
SBP
bacterial infection of ascitic fluid in absence of surgically testable cause
decompensation, pain, fever, worsening distension, shock, AKI
ascite neutrophils > 250
culture +ve 40% - E.Colo
Broad spectrum abx, repeat paracentesis after 48hr
drain ascites
albumin prevents AKI (Sort et al)
Scoring systems in chronic liver disease
MELD
Child - Pugh (ascites, INR, encephalopathy, bilirubin, albumin) 12mo survival
Clif-C-ACLF - 28d mortality (organ dysfunction)
Futility in ACLF
EASL suggest withdrawal of ICU
- 7 days after diagnosis and adequate treatment
- >4 organ failures (CLIF-C-ACLF > 64)
- Liver transplant contraindicated
Diarrhoea definitions
- 3+ loose / liquid stools / day
- 200g + stool / day
- 250ml + stool / day
- Bristol stool chart 5-7
Diarrhoea on critical care
- infection - cross infection / contamination
- electrolyte imbalance
- fluid imbalance
- nursing workload
- skin breakdown
- antimicrobial stewardship
Diarrhoea classification
Mechanism - secretory, osmotic, motoric, exudative
duration - acute < 2 weeks chronic > 4 weeks
Aetiology
- infectious
- bacterial c.diff, salmonella, shigella, e.coli, campylobacter
- viral - norovirus, rotavirus, adenovirus
- non-infectious
- IBD
- pancreatic insufficiency
- short bowel
- food / feeding - intolerances, osmotic
- medication related - antibiotics, pro kinetics, laxatives, chemo/radiotherapy
Mechanisms of antibiotic associated diarrhoea
- direct pro kinetic effect
- microbial modification - excess carbohydrates
- unmetabolised bile salts
- colitis from bacterial overgrowth e.g. c diff
Management of ICU patient with diarrhoea
- infection screening / prevention
- correction of underling cause ? gut perfusion ? medications
- adjust feed e.g. reduce rate, fibre, osmolality
- Fluid balance and replacement
- Electrolye monitoring and replacement
- Skin / barrier protection e.g. bowel management system
- antidiarrhoeal medications
C.difficile
- gram positive spore forming anaerobe
- severe colitis and comlications
- toxin producing - A = intestinal permeability B = colon inflammation
risk factors - Abx - co-amox, clina, cephalopsporins
- PPI
- Age > 60
- chronic care
- exposure
Diarrhoea –> stool test - GDH antigen +ve and toxin +ve = active c.diff
- both negative = no c.diff
- antigen +ve means c.diff in bowel but if toxin -ve not causing infection
C.diff severity
Mild
- WCC normal and < 3 loose stool / day
Moderate
- WCC raised but less than 15
- 3-5 stool
Severe any of
- WCC > 15
- Creatinine > 50% baseline
- temperature > 38.5
- severe colitis on imaging
Life thretaing
- megacolon
- hypotension
- ileus
C.diff management
enteral abx
- Vancomycin PO 125mg ads
- fidaxomicin 2nd line
- severe - Vanc 500mg qds + metronidazole
10 day treatment
faecal transplant, ivies
Ulcerative Colitis
Inflammatory bowel disease characterised by inflammation starting vitally, continuous extension proximally
complications - perforation, adenocarcinoma, haemorrhage, megacolon
Acute severe = truelove witts
- > 6 bloody stool / day
- 1 of fever, HR > 90 Hb < 105, CRP > 30
treatment = steroid, 2nd line, bloods, stool mc/s, sigmoidoscopy
response = < 4 stool, no rectal bleeding
surgical review if continued systemic toxicity, toxic megacolon > 8 stool / day
Crohns disease
chronic complex GI inflammatory condition
variable onset and location
skip lesions, ill involvement, granulomatous inflammation
complications - perforation, fistulas, strictures
IBD immunosuppression
- 5-ASA - mesalazine (nephrotoxicity)
- Thiopurines - azathioprine (myelotoxicity, hepatotoxicity)
- steroids
- Anti-TNF - infliximab, adalibumab
- Anti-metabolite - methotrexate (GI, hepatoxicitity, pneumonitis)
- calcineurin inhibitors - ciclosporin (nephrotoxicity)
HALT-IT trial
TXA bolus and infusion in acute UGI bleed
No difference in mortality, rebleeding, transfusions
Significantly higher VTE